Combination vaccines

Vaccines

Volumn , Issue , 2008, Pages 1069-1101

  Decker, Michael D ^a,b   Edwards, Kathryn M ^a   Bogaerts, Hugues H ^c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANOFI PASTEUR   (France)

^c GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879817345     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3611-1.50042-8     Document Type: Chapter

References (314)

1. Williams JC, Goldenthal KL, Burns DL, et al, (eds). Combined vaccines and simultaneous administration: current issues and perspectives. Ann N Y Acad Sci 754:xi–404, 1995.
2. Breiman R, Goldenthal K, (eds). International Symposium on Combination Vaccines: Proceedings of a Symposium Organized and Sponsored by the National Vaccine Program Office and Held at the National Institutes of Health, 2–4 February 2000. Clin Infect Dis 33(suppl 4):S271–S375, 2001.
3. JD Grabenstein (1995) Immunofacts: Vaccines and Immunologic Drugs St. Louis: Facts and Comparisons
4. Centers for Disease Control and Prevention (2002) General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 51(RR-2), 1-44.
5. R Arnon and MHV Van Regenmortel (1992) Structural basis of antigenic specificity and design of new vaccines. FASEB J 6 3265-3274.
6. KM Edwards, BD Meade, MD Decker, et al. (1995) Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 96 548-557.
7. C Chu, R Schneerson, JB Robbins, et al. (1983) Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates. Infect Immun 40 245-256.
8. O Castillo de Febres, MD Decker, M Estopinan, et al. (1994) Enhanced antibody response in Venezuelan infants immunized with Haemophilus influenzae type β-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J 13 635-639.
9. R Schneerson, JB Robbins, C Chu, et al. (1984) Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates. Infect Immun 45 582-591.
10. P Anderson, M Pichichero and K Edwards (1987) Priming and induction of Haemophilus influenzae type b capsular antibodies in early infancy by Dpo20, an oligosaccharide-protein conjugate vaccine. J Pediatr 111 644-650.
11. T Barington, M Skettrup, L Juul, et al. (1993) Non-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components. Infect Immun 61 432-438.
12. RA Insel (1995) Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. Ann N Y Acad Sci 754 35-47.
13. R Dagan, J Eskola, C Leclerc, et al. (1998) Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun 66 2093-2098.
14. J Banatvala, P Van Damme and S Oehen (2000) Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 19 877-885.
15. European Consensus Group on Hepatitis B Immunity (2000) Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 355 561-565.
16. J Eskola, J Ward, R Dagan, et al. (1999) Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 354 2063-2068.
17. DF Kelly, AJ Pollard and ER Moxon (2005) Immunological memory: the role of B cells in long-term protection against invasive bacterial pathogens. JAMA 294 3019-3023.
18. DM Granoff and R Rappuoli (1997) Are serological responses to acellular pertussis antigens sufficient criteria to ensure that new combination vaccines are effective for prevention of disease? Dev Biol Stand 89 379-389.
19. DM Granoff (1996) Challenges for licensure of new diphtheria, tetanus, acellular pertussis (DTaP) combination vaccines: point. Pediatr Infect Dis J 15 1069-1070.
20. KM Edwards and MD Decker (1996) Challenges for licensure of new diphtheria, tetanus toxoid, acellular pertussis (DTaP) combination vaccines: counterpoint. Pediatr Infect Dis J 15 1070-1073.
21. J Storsaeter, HO Hallander, L Gustafsson, et al. (1998) Levels of antipertussis related to protection after household exposure to Bordetella pertussis. Vaccine 16 1907-1916.
22. JD Cherry, J Gornbein, U Heininger, et al. (1998) A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16 1901-1906.
23. F Zepp, M Knuf, P Habermehl, et al. (1996) Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine. Infect Immun 64 4078-4084.
24. N Guiso, C Capiau, G Carletti, et al. (1999) Intranasal murine model of Bordetella pertussis infection, I: prediction of protection in human infants by acellular vaccines. Vaccine 17 2366-2376.
25. KH Mills, M Ryan, E Ryan, et al. (1998) A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 66 594-602.
26. Poolman J. Comparison of seven licensed Pa vaccines in a mouse respiratory model [abstract]. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 24–27, 1999, abstract 233, p 356.
27. Poolman J. Efficacy of Infanrix in promoting lung clearance of B. pertussis strains expressing pertactin antigenic variants in a mouse respiratory model [abstract]. In Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 24–27, 1999, abstract 234, p 356.
28. C Boursaux-Eude, S Thiberge, G Carletti, et al. (1999) Intranasal murine model of Bordetella pertussis infection, II: sequence variation and protection induced by a tricomponent acellular vaccine. Vaccine 17 2651-2660.
29. KM Edwards and MD Decker (1994) Combination vaccines: hopes and challenges. Pediatr Infect Dis J 13 345-347.
30. MD Decker and KM Edwards (1995) Issues in design of clinical trials of combination vaccines. Ann N Y Acad Sci 754 234-240.
31. KM Edwards and MD Decker (1997) Combination vaccines consisting of acellular pertussis vaccines. Pediatr Infect Dis J 16(Suppl 4), S97-S102.
32. L Gustafsson, HO Hallander, P Olin, et al. (1996) A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 334 349-355.
33. Ad Hoc Group for the Study of Pertussis Vaccines (1988) Placebo-controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events. Lancet 1 955-960.
34. P Olin, F Rasmussen, L Gustafsson, et al. (1997) Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet 350 1569-1577.
35. D Greco, S Salmaso, P Mastrantonio, et al. (1996) A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 334 341-348.
36. Guidance for Industry for the Evaluation of Combination Vaccines for Preventable Diseases Production, Testing and Clinical Studies (Docket No 97N-0029). Rockville, MD, U.S. Food and Drug Administration, 1997.
37. GE King and SC Hadler (1994) Simultaneous administration of childhood vaccines: an important public health policy that is safe and efficacious. Pediatr Infect Dis 13 394-407.
38. PA Offit, J Quarles, MA Gerber, et al. (2002) Addressing parents’ concerns: do multiple vaccines overwhelm or weaken the infant's immune system? Pediatrics 109 124-129.
39. NA Halsey (2001) Combination vaccines: defining and addressing current safety concerns. Clin Infect Dis 33(Suppl), S312-S318.
40. NA Halsey (2001) Safety of combination vaccines: perception versus reality. Pediatr Infect Dis J 20(Suppl), S40-S44.
41. J-F Bach (2002) The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347 911-920.
42. ST Weiss (2002) Eat dirt-the hygiene hypothesis and allergic diseases. N Engl J Med 347 930-931.
43. Stratton K, Wilson CV, McCormick MC (eds). Immunization Safety Review: Multiple Immunizations and Immune Dysfunction. Immunization Safety Review Committee, Board on Health Promotion and Disease Prevention, Institute of Medicine. Washington, DC, National Academy Press, 2002.
44. RT Chen, SC Rastogi, JR Mullen, et al. (1994) The Vaccine Adverse Event Reporting System (VAERS). Vaccine 12 542-550.
45. L Greenberg and DS Fleming (1948) The immunizing efficacy of diphtheria toxoid when combined with various antigens. Can J Public Health 39 131-135.
46. V Spiller, JM Barnes, LB Holt, et al. (1955) Immunization against diphtheria and whooping-cough: combined versus separate inoculations. BMJ 2 639-642.
47. MA Aprile and AC Wardlaw (1966) Aluminum compounds as adjuvants for vaccines and toxoids in man: a review. Can J Public Health 57 343-354.
48. M Knuf, P Habermehl, J Faber, et al. (2006) Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life. Vaccine 24 5627-5636.
49. R Berger, M Just and R Gluck (1988) Interference between strains in live virus vaccines, I: combined vaccination with measles, mumps and rubella vaccine. J Biol Stand 16 269-273.
50. M Beck, S Smerdel, I Dedic, et al. (1986) Immune response to Edmonston-Zagreb measles virus strain in monovalent and combined MMR vaccine. Dev Biol Stand 65 95-100.
51. AJ Schwarz, JE Jackson, NJ Ehrenkranz, et al. (1975) Clinical evaluation of a new measles-mumps-rubella vaccine. Am J Dis Child 129 1408-1412.
52. M Just, R Berger, R Gluck, et al. (1986) Evaluation of a combined vaccine against measles-mumps-rubella produced on human diploid cells. Dev Biol Stand 65 25-27.
53. R Berger and M Just (1988) Interference between strains in live virus vaccines. II: combined vaccination with varicella and measles-mumps-rubella vaccine. J Biol Stand 16 275-279.
54. TM Francis Jr, JA Napier, RB Voight, et al. (1957) Evaluation of the 1954 Field Trial of Poliomyelitis Vaccine (Final Report) Ann Arbor: University of Michigan
55. H Cohen and J Nagel (1984) Two injections of diphtheria-tetanus-pertussis-polio vaccine as the backbone of a simplified immunization schedule in developing countries. Rev Infect Dis 6(Suppl), S350-S351.
56. AL van Wezel, G van Steenis, P van der Marel, et al. (1984) Inactivated poliovirus vaccine: current production methods and new developments. Rev Infect Dis 6(Suppl), S335-S340.
57. J Salk (1984) One-dose immunization against paralytic poliomyelitis using a noninfectious vaccine. Rev Infect Dis 6(Suppl), S444-S450.
58. C Ferreccio, J Clemens, A Avendano, et al. (1991) The clinical and immunologic response of Chilean infants to Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine coadministered in the same syringe with diphtheria-tetanus toxoids-pertussis vaccine at two, four, and six months of age. Pediatr Infect Dis J 10 764-771.
59. JD Clemens, C Ferreccio, M Levine, et al. (1992) Impact of Haemophilus influenzae type b polysaccharide-tetanus conjugate vaccine on responses to concurrently administered diphtheria-tetanus-pertussis vaccine. JAMA 267 673-678.
60. D Scheifele, L Barreto, W Meekison, et al. (1993) Can Haemophilus influenzae type β-tetanus toxoid conjugate vaccine be combined with diphtheria toxoid-pertussis vaccine-tetanus toxoid? Can Med Assoc J 149 1105-1112.
61. R Gold, D Scheifele, L Barreto, et al. (1994) Safety and immunogenicity of Haemophilus influenzae vaccine (tetanus toxoid conjugate) administered concurrently or combined with diphtheria and tetanus toxoids, pertussis vaccine and inactivated poliomyelitis vaccine to healthy infants at two, four, and six months of age. Pediatr Infect Dis J 13 348-355.
62. A Avendano, C Ferreccio, R Lagos, et al. (1993) Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine does not depress serologic responses to diphtheria, tetanus, or pertussis antigens when coadministered in the same syringe with diphtheria-tetanus-pertussis vaccine at two, four, and six months of age. Pediatr Infect Dis J 12 638-643.
63. SL Kaplan, BA Lauer, MA Ward, et al. (1994) Immunogenicity and safety of Haemophilus influenzae type β-tetanus protein conjugate vaccine alone or mixed with diphtheria-tetanus-pertussis vaccine in infants. J Pediatr 124 323-327.
64. MA Miller, CK Meschievitz, GA Ballanco, et al. (1995) Safety and immunogenicity of PRP-T combined with DTP: excretion of capsular polysaccharide and antibody response in the immediate post-vaccination period. Pediatrics 95 522-527.
65. NT Begg, E Miller, CK Fairley, et al. (1995) Antibody responses and symptoms after DTP and either tetanus or diphtheria Haemophilus influenzae type b conjugate vaccines given for primary immunisation by separate or mixed injection. Vaccine 13 1547-1550.
66. OS Levine, R Lagos, GA Losonsky, et al. (1996) No adverse impact on protection against pertussis from combined administration of Haemophilus influenzae type b conjugate and diphtheria-tetanus toxoid-pertussis vaccines in the same syringe. J Infect Dis 174 1341-1344.
67. R Dagan, C Botujansky, N Watemberg, et al. (1994) Safety and immunogenicity in young infants of Haemophilus β-tetanus protein conjugate vaccine, mixed in the same syringe with diphtheria-tetanus-pertussis-enhanced inactivated poliovirus vaccine. Pediatr Infect Dis J 13 356-362.
68. EK Mulholland, A Hoestermann, JI Ward, et al. (1996) The use of Haemophilus influenzae type β-tetanus toxoid conjugate vaccine mixed with diphtheria-tetanus-pertussis vaccine in Gambian infants. Vaccine 14 905-909.
69. F Bell, A Martin, C Blondeau, et al. (1996) Combined diphtheria, tetanus, pertussis, and Haemophilus influenzae type b vaccines for primary immunisation. Arch Dis Child 75 298-303.
70. K Hoppenbrouwers, R Lagos, B Swennen, et al. (1998) Safety and immunogenicity of an Haemophilus influenzae type β-tetanus toxoid conjugate (PRP-T) and diphtheria-tetanus-pertussis (DTP) combination vaccine administered in a dual-chamber syringe to infants in Belgium and Chile. Vaccine 16 921-927.
71. J Langue, C Ethevenaux, A Champsaur, et al. (1999) Safety and immunogenicity of Haemophilus influenzae type β-tetanus toxoid conjugate, presented in a dual-chamber syringe with diphtheria-tetanus-pertussis and inactivated poliomyelitis combination vaccine. Eur J Pediatr 158 717-722.
72. OO Araujo, E Forleo-Neto and GN Vespa (2001) Associated or combined vaccination of Brazilian infants with a conjugate Haemophilus influenzae type b (Hib) vaccine, a diphtheria ± tetanus ± whole-cell pertussis vaccine and IPV or OPV elicits protective levels of antibodies against Hib. Vaccine 19 367-375.
73. JL Coulehan, C Hallowell, RH Michaels, et al. (1983) Immunogenicity of a Haemophilus influenzae type b vaccine in combination with diphtheria-pertussis-tetanus vaccine in infants. J Infect Dis 148 530-534.
74. J Eskola, H Kayhty, LK Gordon, et al. (1988) Simultaneous administration of Haemophilus influenzae type b capsular polysaccharide-diphtheria toxoid conjugate vaccine with routine diphtheria-tetanus-pertussis and inactivated poliovirus vaccinations of childhood. Pediatr Infect Dis J 7 480-484.
75. EK Mulholland, VI Ahonkhai, AM Greenwood, et al. (1993) Safety and immunogenicity of Haemophilus influenzae type β- Neisseria meningitidis group B outer membrane protein complex conjugate vaccine mixed in the syringe with diphtheria-tetanus-pertussis vaccine in young Gambian infants. Pediatr Infect Dis J 12 632-637.
76. PR Paradiso, DA Hogerman, DV Madore, et al. (1993) Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants. Pediatrics 92 827-832.
77. PR Paradiso (1995) Combination vaccines for diphtheria, tetanus, pertussis, and Haemophilus influenzae type b. Ann N Y Acad Sci 754 108-113.
78. SB Black, HR Shinefield, P Ray, et al. (1993) Safety of combined oligosaccharide conjugate Haemophilus influenzae type b (HbOC) and whole cell diphtheria-tetanus toxoids-pertussis vaccine in infancy. Pediatr Infect Dis J 12 981-985.
79. IG Jones, H Tyrrell, A Hill, et al. (1998) Randomised controlled trial of combined diphtheria, tetanus, whole-cell pertussis vaccine administered in the same syringe and separately with Haemophilus influenzae type b vaccine at two, three, and four months of age. Vaccine 16 109-113.
80. Asensi-Botet F, Viviani S, Veronese A, et al. Safety, tolerability, and immunogenicity of a combined DTPHIB (diphtheria, tetanus, pertussis, Haemophilus influenzae type B-CRM 197 conjugate full liquid) vaccine [poster 12-PT291]. Presented at the 23rd International Congress of Pediatrics, Beijing, China, September 2001.
81. R Lagos, I Horwitz, J Toro, et al. (1996) Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr Infect Dis J 15 216-222.
82. DW Scheifele (1996) Recent trends in pediatric Haemophilus influenzae type b infections in Canada. Immunization Monitoring Program, Active (IMPACT) of the Canadian Paediatric Society and the Laboratory Centre for Disease Control. Can Med Assoc J 154 1041-1047.
83. D Scheifele, R Gold, V Marchessault, et al. (1996) Failures after immunization with Haemophilus influenzae type b vaccines-1991–1995. Can Commun Dis Rep 22 17-20.
84. Centers for Disease Control and Prevention (1996) Summary of notifiable diseases, United States, 1996. MMWR 45 73.
85. J Aristégui, E Garrote, A Gonzalez, et al. (1997) Immune response to a combined hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine administered to infants at 2, 4, and 6 months of age. Vaccine 15 7-9.
86. Black S, Shinefield H, Ray P, et al. Safety and immunogenicity of combined DTP-hepatitis B-PRP-T vaccine (DTPHH) (SmithKline Beecham) in infants [abstract]. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17–20, 1995, abstract G73.
87. S Riedemann, G Reinhardt, J Jara, et al. (1997) Reactogenicity and immunogenicity of a diphtheria-tetanus-pertussis-hepatitis B and Haemophilus influenzae type B vaccine (DTPw-HBV-Hib) versus separately administered DTPw-HBV and Hib vaccines in infants [abstract]. J Paediatr Child Health 33(Suppl 1), S121.
88. S Riedemann, G Reinhardt, J Jara, et al. (2002) Immunogenicity and reactogenicity of combined versus separately administered DTPw-HBV and Hib vaccines given to healthy infants at 2, 4, and 6 months of age, with a booster at 18 months. Int J Infect Dis 6 215-222.
89. KM Win, M Aye, H Htay-Htay, et al. (1997) Comparison of separate and mixed administration of DTPw-HBV and Hib vaccines: immunogenicity and reactogenicity profiles. Int J Infect Dis 2 79-84.
90. T Nolan, G Hogg, MA Darcy, et al. (2001) A combined liquid Hib (PRP-OMPC), hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine: controlled studies of immunogenicity and reactogenicity. Vaccine 19 2127-2137.
91. S Gatchalian, M Reyes, N Bernal, et al. (2005) A new DTPw-HBV/Hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth. Human Vaccines 1 e6-e11.
92. KH Hla, SA Thein, A Aye, et al. (2006) Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content. Pediatr Infect Dis J 25 706-712.
93. Gatchalian S, Dobbelaere K, Han HH, Boutriau D. Immunogenicity and safety of 3 doses of Tritanrix-HepB/Hib-MenAC vaccine dministered to infants at 6, 10 and 14 weeks of age [abstract]. In: Abstracts of the 14th International Pathogenic Neisseria Conference, Milwaukee, WI, September 5–10, 2004, p 146.
94. Y Poovorawan, A Theamboonlers, S Sanpavat, et al. (1999) Comparison study of combined DTPw-HB vaccines and separate administration of DTPw and HB vaccines in Thai children. Asian Pac J Allergy Immunol 17 113-120.
95. V Prikazsky and HL Bock (2001) Higher anti-hepatitis b response with combined DTPw-HBV vaccine compared with separate administration in healthy infants at 3, 4, and 5 months of age in Slovakia. Int J Clin Pract 55 156-161.
96. JI Santos, A Martin, T De Leon, et al. (2002) DTPw-HB and Hib primary and booster vaccination: combined versus separate administration to Latin American children. Vaccine 20 1887-1893.
97. Ramkissoon A, Coovadia HM, Jugnundan P, et al. Antibody responses and safety following a pentavalent vaccine: combined DTP-hepatitis B- Haemophilus influenzae type b (Hib) at 2, 4, and 6 months of age [abstract]. In: Abstracts of the Seventh International Congress for Infectious Diseases, Hong Kong, June 10–13, 1996, p 72.
98. G Papaevangelou, E Karvelis, D Alexiou, et al. (1995) Evaluation of a combined tetravalent diphtheria, tetanus, whole-cell pertussis and hepatitis B candidate vaccine administered to healthy infants according to a three-dose vaccination schedule. Vaccine 13 175-178.
99. V Usonis, V Bakasenas, D Taylor and P Vandepapeliere (1996) Immunogenicity and reactogenicity of a combined DTPw-hepatitis B vaccine in Lithuanian infants. Eur J Pediatr 155 189-193.
100. J Diez-Delgado, R Dal-Re, M Llorente, et al. (1997) Hepatitis B component does not interfere with the immune response to diphtheria, tetanus, and whole-cell Bordetella pertussis components of a quadrivalent (DTPw-HB) vaccine: a controlled trial in healthy infants. Vaccine 15 1418-1422.
101. Aspinall S, Breedt J, Venter E, et al. Safety and immunogenicity of three lots of a fully liquid DTP-HepB-Hib vaccine administered to healthy infants at 6, 10, and 14 weeks of age [abstract]. In: Abstracts of the 24th Annual Meeting of the European Society for Pediatric Infectious Diseases, Basel, Switzerland, May 2006.
102. G Kanra, A Kara and O Demiralp (2006) Safety and immunogenicity of a new fully liquid DTPw-HepB-HiB combination vaccine in infants. Human Vaccines 2 155-160.
103. Gatchalian S, Dobbelaere K, De Vleeschauwer I, et al. Antibody persistence and immune memory in 10-month-old infants primed with Tritanrix-HepB/Hib-MenAC at 6, 10, 14 weeks of age [abstract]. In Abstracts of the 14th International Pathogenic Neisseria Conference, Milwaukee, WI, September 5–10, 2004, p 145.
104. L Gustafsson, HO Hallander and P Olin Seven year report: pertussis surveillance in Sweden; progress report October 1997–September 2004 with an executive summary. Swedish Institute for Infectious Disease Control (SMI), June 16, 2005. Online. Available at: http://www.smittskyddsinstitutet.se/SMItemplates/Article____5894.aspx Accessed September 1, 2006
105. J Eskola, RM Olander, T Hovi, et al. (1996) Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 348 1688-1692.
106. Eskola J, Litmanen L, Saarinen L, et al. Responses at 24 months to a combined DTaP-Hib conjugate vaccine in children vaccinated with the same vaccines at 4 and 6 months [abstract]. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15–18, 1996, abstract G060.
107. SA Halperin, HD Davies, L Barreto, et al. (1997) Safety and immunogenicity of two inactivated poliovirus vaccines in combination with an acellular pertussis vaccine and diphtheria and tetanus toxoids in seventeen- to nineteen-month-old infants. J Pediatr 130 525-531.
108. David T, Cadoz M, Gobert P, et al. Acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated polio vaccine (AcPDT IPV): comparison to a DTP-IPV with a whole cell pertussis component (WcPDT IPV) in infants [abstract]. In Abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 29–October 2, 1991, abstract 60.
109. Lagos R, Kotloff K, Hoffenbach A, et al. Clinical response to pentavalent parenteral diphtheria, tetanus, acellular pertussis (DTaP), inactivated polio (eIPV) and Haemophilus influenzae b (Hib) conjugate vaccine in 2, 4, and 6 month old Chilean infants [abstract]. In Abstracts of the 35th Annual Meeting of the Infectious Diseases Society of America, San Francisco, September, 1997, abstract 609.
110. R Lagos, K Kotloff, A Hoffenbach, et al. (1998) Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, and Haemophilus influenzae type b conjugate antigens in two-, four-, and six-month-old Chilean infants. Pediatr Infect Dis J 17 294-304.
111. L Nilsson, G Faldella, JM Jacquet, et al. (2005) A fourth dose of DTPa-IPV vaccine given to 4–6 year old children in Italy and Sweden following primary vaccination at 3, 5 and 11–12 months of age. Scand J Infect Dis 37 221-229.
112. H Marshall, T Nolan, D Roberton, et al. (2006) A comparison of booster immunisation with a combination DTPa-IPV vaccine or DTPa plus IPV in separate injections when co-administered with MMR, at age 4–6 years. Vaccine 24 6120-6128.
113. S Black, LR Friedland, A Schuind and B Howe (2006) For the GlaxoSmithKline DTaP-IPV Vaccine Study Group. Immunogenicity and safety of a combined DTaP-IPV vaccine compared with separate DTaP and IPV vaccines when administered as pre-school booster doses with a second dose of MMR vaccine to healthy children aged 4–6 years. Vaccine 24 6163-6171.
114. CL Collins, P Salt, N McCarthy, et al. (2004) Immunogenicity and safety of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine as a pre-school booster in UK children. Vaccine 22 4262-4269.
115. J Southern, N Andrews, M Burrage and E Miller (2005) Immunogenicity and reactogenicity of combined acellular pertussis/tetanus/low dose diphtheria vaccines given as a booster to UK teenagers. Vaccine 23 3829-3835.
116. Hronowski L, Rohrbaugh J, Prebula R, et al. Immunogenicity of a new Haemophilus influenzae type b polysaccharide-tetanus toxoid (Hib-TT) conjugate vaccine and the immunogenicities of the individual components in the pentavalent Hib-TT + DTaP + IPV vaccine [abstract]. In Abstracts of the 93rd General Meeting of the American Society for Microbiology, Washington, DC, 1993, abstract E78.
117. Gyhrs AG, Olsen A, Petersen JV, et al. T-cell immunity in children vaccinated with hydrogen peroxide detoxified PT in a DTaP-IPV combination vaccine [abstract]. In: Abstracts of the 95th General Meeting of the American Society for Microbiology, San Francisco, September 1995, abstract E92.
118. A Gyhrs, E Lyngholm, SO Larsen, et al. (1999) Safety and immunogenicity of a tetravalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine. Scand J Infect Dis 31 579-585.
119. J Diez-Domingo, JD Delgado, A Ballester, et al. (2005) Immunogenicity and reactogenicity of a combined adsorbed tetanus toxoid, low dose diphtheria toxoid, five component acellular pertussis and inactivated polio vaccine in six-year-old children. Pediatr Infect Dis J 24 219-224.
120. SA Halperin, B Smith, M Russell, et al. (2000) Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults. Pediatr Infect Dis J 19 276-283.
121. Saenger R, Wolter J, Schuerman L. A reduced-antigen diphtheria-tetanus-acellular pertussis-IPV vaccine for booster vaccination of 4 to 8 year old children [abstract]. In Abstracts of the 21st Annual Meeting of the European Society for Pediatric Infectious Diseases, Oslo, Norway, May 2003, abstract 247.
122. R Vergara, M Tregnaghi, J Ussher, et al. (2005) Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur J Pediatr 164 377-382.
123. E Grimprel, F von Sonnenburg, R Sanger, et al. (2005) Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults. Vaccine 23 3657-3667.
124. JM Langley, G Predy, R Guasparini, et al. (2007) An adolescent–adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity, but less reactogenicity in children 4–6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine. Vaccine 25 1121-1125.
125. MB Rennels, JA Englund, DI Bernstein, et al. (2000) Diminution of the anti-polyribosylribitol phosphate response to a combined diphtheria-tetanus-acellular pertussis Haemophilus influenzae type b vaccine by concurrent inactivated poliovirus vaccination. Pediatr Infect Dis J 19 417-423.
126. RS Daum, CE Zenko, GZ Given, et al. (2000) Absence of a significant interaction between a Haemophilus influenzae conjugate vaccine combined with a diphtheria toxoid, tetanus toxoid and acellular pertussis vaccine in the same syringe and inactivated polio vaccine. Pediatr Infect Dis J 19 710-717.
127. G Kanra, M Ceyhan, Z Ecevit, et al. (1995) Primary vaccination of infants with a combined diphtheria-tetanus-acellular pertussis-hepatitis B vaccine. Pediatr Infect Dis J 14 998-1000.
128. V Usonis, V Bakasenas, P Willems, et al. (1997) Feasibility study of a combined diphtheria-tetanus-acellular pertussis-hepatitis B (DTPa-HBV) vaccine, and comparison of clinical reactions and immune responses with diphtheria-tetanus-acellular pertussis (DTPa) and hepatitis B vaccines applied as mixed or injected into separate limbs. Vaccine 15 1680-1686.
129. G Giammanco, A Moiraghi, C Zotti, et al. (1998) Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-hepatitis B vaccine administered according to two different primary vaccination schedules. Vaccine 16 722-726.
130. DP Greenberg, VK Wong, S Partridge, et al. (2002) Safety and immunogenicity of a combination diphtheria-tetanus toxoids-acellular pertussis-hepatitis B vaccine administered at two, four, and six months of age compared with monovalent hepatitis B vaccine administered at birth, one month, and six months of age. Pediatr Infect Dis J 21 769-777.
131. Andre F. The way forward-combined vaccines [abstr SD5]. In: Extended Abstracts from the 9th Triennial International Symposium on Viral Hepatitis and Liver Disease, Rome, 1996.
132. SH Yeh, JI Ward, S Partridge, et al. (2001) Safety and immunogenicity of a pentavalent diphtheria, tetanus, pertussis, hepatitis B, and polio combination vaccine in infants. Pediatr Infect Dis J 20 973-980.
133. R Gylca, V Gylca and O Benes (2001) A new DTPa-HBV-IPV vaccine co-administered with Hib, compared to a commercially available DTPw-IPV: Hib vaccine co-administered with HBV, given at 6, 10, and 14 weeks following HBV at birth. Vaccine 19 825-833.
134. PEDIARIX Prescribing Information. Philadelphia: SmithKline Beecham Pharmaceuticals, December 2002, pp 17–18.
135. Black SB, Ray PM, Lewis EM, et al. Lower reactogenicity of two different DTaP preparations in young children versus combined DTaP-IPV-Hepatitis B [abstract]. In Abstracts of the 43rd Annual Meeting of the Infectious Diseases Society of America, San Francisco, October 2003, p 217.
136. LA Thompson, M Irigoyen, LA Matiz, et al. (2006) The Impact of DTaP-IPV-HB Vaccine on Use of Health Services for Young Infants. Pediatr Infect Dis J 25 826-831.
137. V Usonis and V Bakasenas (1999) Does concomitant injections of a combined diphtheria-tetanus-acellular pertussis-hepatitis B, virus-inactivated polio virus vaccine influence the reactogenicity and immunogenicity of commercial Haemophilus influenzae type b conjugate vaccine? Eur J Pediatr 158 398-402.
138. Schmitt HJ, Knuf M, Beutel K, et al. Antibody persistence, PRP-specific immune memory and booster response in children primed with a new combination vaccine DTPa-HBV-IPV given as either a mixed or separate injection [abstract]. In: Abstracts of the 18th Annual Meeting of the European Society for Paediatric Infectious Diseases, Noordwijk, the Netherlands, May 3–5, 2000, pp 37–38.
139. Infanrix Hexa European Public Assessment Report, Revision 1. London, European Agency for the Evaluation of Medicinal Products, January 15, 2002. Online. Available at: http://www.emea.eu.int/humandocs/Humans/EPAR/infanrixhexa/infanrixhexa.htm Retrieved September 2, 2006
140. Zepp F, Schuind A, Meyer C, et al. Reactogenicity of a new pentavalent combination, DTPa-HBV-IPV administered with Hib vaccine, in comparison with widely used commercial vaccines, in 5,472 subjects [abstract]. In: Abstracts of the 17th Annual Meeting of the European Society for Paediatric Infectious Diseases, Crete, Greece, May 1999, p 72.
141. Zepp F, Knuf M, Schuerman L, et al. A combined DTPa-HBV-IPV for use (as a fourth dose) in the second year of life [abstract]. In Proceedings of the 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, November 18–21, 1999, p 155.
142. A Kovel, ER Wald, N Guerra, et al. (1992) Safety and immunogenicity of acellular diphtheria-tetanus-pertussis and Haemophilus conjugate vaccines given in combination or at separate injection sites. J Pediatr 120 84-87.
143. Product Information (1998) TriHIBit. Physician's Desk Reference Montvale NJ: Medical Economics 2138-2142.
144. Shinefield H, Black S, Adelman T, et al. Safety and immunogenicity of DTaP-HbOC-α combined oligosaccharide conjugate (HbOC, HibTITER) Haemophilus influenzae type b and acellular DTP vaccine (DTaP) in toddlers [abstract]. In: Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, October 11–14, 1992, abstract 306.
145. M Rennels, M Hohenboken, K Reisinger, et al. (1998) Comparison of acellular pertussis-diphtheria-tetanus toxoids and Haemophilus influenzae type b vaccines administered separately versus combined in younger versus older toddlers. Ped Infect Dis J 17 164-166.
146. Liese JG, Harzer E, Hosbach P, et al. Immunogenicity of a combined DTaP-PRP-D conjugate vaccine compared to separate injections in infants [abstract]. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15–18, 1996, abstract G106.
147. Liese JG, Harzer E, Hosbach P, et al. Hib antibody response of a combined DTaP-PRP-T conjugate vaccine compared to separate injections in infants [abstract]. In: Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15–18, 1996, abstract G105.
148. Hoppenbrouwers K, Kanra G, Silier T, et al. Priming effect of the combined DTaP/Act-HIB vaccine [abstract]. In Abstracts of the 15th Annual Meeting of the European Society for Paediatric Infectious Diseases, Paris, May 1997, abstract 73.
149. ME Pichichero, T Latiolais, DI Bernstein, et al. (1997) Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type β-tetanus toxoid vaccine in two-, four-, and six-month-old infants. Pediatr Infect Dis J 16 863-870.
150. Schmitt HJ. Immunogenicity and reactogenicity of 2 Hib tetanus conjugate vaccines administered by reconstituting with DTaP or given as separate injections [abstract]. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17–20, 1995, abstract G63.
151. HJ Schmitt, F Zepp, S Muschenborn, et al. (1998) Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant DTPa primary and booster immunizations. Eur J Pediatr 157 208-214.
152. Shinefield H, Black S, Ray P, et al. Safety of combined acellular pertussis DTaP-HbOC vaccine (Lederle-Praxis) in infants [abstract]. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17–20, 1995, abstract G72.
153. CY Lee, J Thipphawong, LM Huang, et al. (1999) An evaluation of the safety and immunogenicity of a five-component acellular pertussis, diphtheria, and tetanus toxoid vaccine (DTaP) when combined with a Haemophilus influenzae type β-tetanus toxoid conjugate vaccine (PRP-T) in Taiwanese infants. Pediatrics 103 25-30.
154. P Begue, J Stagnara, F Vie-Le-Sage, et al. (1997) Immunogenicity and reactogenicity of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccines given concurrently with Haemophilus type b conjugate vaccine or as pentavalent vaccine. Pediatr Infect Dis J 16 787-794.
155. Thipphawong J, Baretto L, Mills E, et al. A fully-liquid, acellular pertussis vaccine combined with IPV and Hib vaccines (DTaP-IPV-PRP-T) is safe and immunogenic without significant interactions (Workshop W3E). In Abstracts of the International Conference on Acute Respiratory Infections, Canberra, Australia, July 7–10, 1997.
156. Mills E, Russell M, Cunning L, et al. A fully liquid acellular pertussis vaccine combined with IPV and Hib vaccines (DTaP-IPV-PRP-T) is safe and immunogenic without significant interaction [abstract]. In: Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 28-October 1, 1997, abstract G95.
157. N Knutsson, B Trollfors, J Taranger, et al. (2001) Immunogenicity and reactogenicity of diphtheria, tetanus, and pertussis toxoids combined with inactivated polio vaccine, when administered concomitantly with or as a diluent for a Hib conjugate vaccine. Vaccine 19 4396-4403.
158. Langue J, David T, Roussel F, et al. Safety and immunogenicity of DTaP-IPV and Act-HIB vaccines administered either combined or separately to infants at 2, 3, and 4 months of age [abstract]. In: Abstracts of the 15th Annual Meeting of the European Society for Paediatric Infectious Diseases, Paris, May 1997, abstract 79.
159. Hoffenbach A, Langue J, Mallet E, et al. Influence of combining DTaP-IPV and Act-HIB vaccines and of changing the primary immunization schedule on the antibody response to Haemophilus influenzae type b [abstract]. In Abstracts of the 15th Annual Meeting of the European Society for Paediatric Infectious Diseases, Paris, May 1997, abstract 80.
160. E Mallet, P Fabre, E Pines, et al. (2000) Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants. Pediatr Infect Dis J 19 1119-1127.
161. Zepp F, Schuind A, Habermehl P, et al. Evolution of combination vaccines: comparison of two candidate vaccines with licensed vaccine [abstract]. In: Abstracts of the 18th Annual Meeting of the European Society for Pediatric Infectious Diseases, Noordwijk, the Netherlands, May 3–5, 2000, pp 38–39.
162. MM Blatter, KS Reisinger, DR Terwelp, et al. (1998) Immunogenicity of a combined diphtheria, tetanus, acellular pertussis (DT-tricomponent Pa)-hepatitis B (HB)-inactivated poliovirus (IPV) admixed with Haemophilus influenzae type B (Hib) vaccine in infants. Pediatr Res 43(4, pt 2), 141A.
163. HJ Schmitt, M Knuf, E Ortiz, et al. (2000) Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J Pediatr 137 304-312.
164. Cohen R, Ortiz E, Wollaert L, et al. Final Study Report for Clinical Trial 217744/025: DTPa-HBV-IPV-025. Rixensart, Belgium, GlaxoSmithKline Biologicals, 1999.
165. M Avdicova, V Prikazsky, H Hudeckova, et al. (2002) Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. Eur J Pediatr 161 581-587.
166. D Hogerman, FJ Malinoski, DV Madore, et al. (1993) Safety and immunogenicity of DTaP-HbOC in toddlers primed by DTP and HbOC as separate injections or DTP-HbOC combination vaccine. Pediatr Res 33 171A.
167. RS Daum, CE Zenko, GZ Given, et al. (2001) Magnitude of interference after diphtheria-tetanus toxoids-acellular pertussis/ Haemophilus influenzae type b capsular polysaccharide-tetanus vaccination is related to the number of doses administered. J Infect Dis 184 1293-1299.
168. Bell F, Heath P, Shackley F, et al. Effect of reconstitution with an acellular pertussis, diphtheria, tetanus vaccine on antibody response to Hib vaccine (PRP-T) [abstract]. In: Abstracts of the 15th Annual Meeting of the European Society for Paediatric Infectious Diseases, Paris, May 1997, abstract 69.
169. Bell F, Heath P, Shackley F, et al. Immunological memory to Hib following combined acellular pertussis, diphtheria, tetanus/Hib vaccine. Presented at the Paediatric Research Society Meeting, Sheffield, England, September 1997.
170. Mallet E, Hoffenbach A, Salomon H, et al. Primary immunization with combined, acellular DTaP-IPV-Act-HIB vaccine given at 2-3-4 or 2-4-6 months of age [abstract]. In: Abstracts of the 14th Annual Meeting of the European Society for Paediatric Infectious Diseases, Elsinore, Denmark, May 1996. abstract 19.
171. Mallet E, Hoffenbach A, Pines E, et al. Immunogenicity of the fourth dose of a combined DTaP-IPV/Act-HIB vaccine administered at 15 months of age to children primed either at 2, 3, and 4 or at 2, 4, and 6 months of age [abstract]. In Abstracts of the 15th Annual Meeting of the European Society for Paediatric Infectious Diseases, Paris, May 1997, abstract 81.
172. RM Carlsson, BA Claesson, U Selstam, et al. (1998) Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine- Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr Infect Dis J 17(11), 1026-1033.
173. MH Slack, D Schapira, RJ Thwaites, et al. (2001) Immune response of premature infants to meningococcal serogroup C and combined diphtheria-tetanus toxoids-acellular pertussis- Haemophilus influenzae type b conjugate vaccines. J Infect Dis 184 1617-1620.
174. Meyer CU, Schmidtke P, Habermehl P, et al. Mixed administration of DTaP/Hib vaccine has no impact on the generation of pertussis-specific cell-mediated immune (CMI) responses [abstract]. In: Abstracts of the 35th Annual Meeting of the Infectious Diseases Society of America, San Francisco, September 17–20, 1997, abstract 585.
175. Zepp F, Meyer CU, Schmidtke P, et al. Established pertussis-specific T-cellular immune responses remain stable after vaccination with multivalent DTPa-Hib combination vaccines [abstract]. In: Abstracts of the 36th Annual Meeting of the Infectious Diseases Society of America, Denver, 1998, abstract 699 Fr.
176. Dagan R, Igbaria K, Piglansky L, et al. Immunogenicity of a combined diphtheria, tetanus, acellular pertussis, inactivated poliovirus and H. influenzae type β-tetanus conjugate vaccine (DTPa-IPV-Hib) in infants [abstract]. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, September 15–18, 1996, abstract G59.
177. R Dagan, K Igbaria, L Piglansky, et al. (1997) Safety and immunogenicity of a combined pentavalent diphtheria, tetanus, acellular pertussis, inactivated poliovirus and Haemophilus influenzae type β-tetanus conjugate vaccine in infants, compared with a whole cell pertussis pentavalent vaccine. Pediatr Infect Dis J 16 1113-1121.
178. SA Halperin, J King, B Law, et al. (1999) Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses. Clin Infect Dis 28 995-1001.
179. R Dagan, J Amir, S Ashkenazi, et al. (2001) Early response to nonconjugated polyribosylribitol phospate challenge as evidence of immune memory after combined diphtheria-tetanus-pertussis-polio- Haemophilus influenzae type b primary vaccination. Pediatr Infect Dis J 20 587-592.
180. Zepp F, Meyer CU, Kowalzol F, et al. Evaluation of the immunological memory induced by primary vaccination with Haemophilus influenzae type b (Hib) tetanus conjugate vaccine co-administered with various DTPa-based vaccines [abstract]. In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26–29, 1999.
181. HJ Schmitt, R Von Kries, B Hassenpflug, et al. (2001) Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/ H. influenzae type b combination vaccines. Pediatr Infect Dis J 20 767-774.
182. E Vidor, A Hoffenbach and MA Fletcher (2001) Haemophilus influenzae type b vaccine: reconstitution of lyophilised PRP-T vaccine with a pertussis-containing paediatric combination vaccine, or a change in the primary series immunisation schedule, may modify the serum anti-PRP antibody responses. Curr Med Res Opin 17 197-209.
183. TY Lin, YH Wang, LY Chang, et al. (2003) Safety and immunogenicity of a diphtheria, tetanus, and acellular pertussis-inactivated poliovirus vaccine/ Haemophilus influenzae type B combination vaccine administered to Taiwanese infants at 2, 4, and 6 months of age. Chang Gung Med J 26 315-322.
184. DP Greenberg, VK Wong, S Partridge, et al. (2000) Immunogenicity of a Haemophilus influenzae type β-tetanus toxoid conjugate vaccine when mixed with a diphtheria-tetanus-acellular pertussis-hepatitis B combination vaccine. Pediatr Infect Dis J 19 1135-1140.
185. ME Pichichero and S Passador (1997) Administration of combined diphtheria and tetanus toxoids and pertussis vaccine, hepatitis B vaccine, and Haemophilus influenzae type b (Hib) vaccine to infants and response to a booster dose of Hib conjugate vaccine. Clin Infect Dis 25 1378-1384.
186. G Gabutti, F Zepp, L Schuerman, et al. (2004) Cooperative Italian Group for the Study of Combined Vaccines. Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV Combination vaccine co-administered with a Hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections at 3, 5 and 11 months of age. Scand J Infect Dis 36 585-592.
187. J Aristégui, R Dal-Ré, J Diez-Delgado, et al. (2003) Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Vaccine 21 3593-3600.
188. E Mills, R Gold, J Thipphawong, et al. (1998) Safety and immunogenicity of a combined five-component pertussis-diphtheria-tetanus-inactivated poliomyelitis- Haemophilus b conjugate vaccine administered to infants at two, four, and six months of age. Vaccine 16 576-585.
189. Capeding MR, Unalivia L, Victorio MV, et al. Immunogenicity and safety of a fully liquid DTPa-IPV-HIB vaccine in infants at 6, 10, 14 weeks of age (EPI schedule). 3rd World Congress Of Pediatric Infectious Diseases—WSPID, Santiago, Chile, November 19–23, 2002, abstract 59.
190. TY Lin, YH Wang, LY Chang, et al. (2007) A fully liquid diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis- Haemophilus influenzae type b conjugate vaccine: immunogenicity and safety of primary vaccination in Taiwanese infants. Int J Infect Dis 11 129-136.
191. Lin TY, Wang YH, Huang YC, et al. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine. Int J Infect Dis March 7, 2007 (ahead of print).
192. Blatter MM, Noriega F. On behalf of the Pentacel Investigators. Immunogenicity and Safety of Pentacel™ (Diphtheria-Tetanus-Acellular Pertussis-Inactivated Poliovirus- Haemophilus influenzae type b Vaccine) in U.S. Infants 2, 4, and 6 Months of Age [abstract]. In: Abstracts of the 11th International Congress on Infectious Diseases, Cancun, Mexico, March 4–7 2004, abstract 18.028.
193. Noriega F, Tomovici A, Jemiolo D, Greenberg DP. Safety and immunogenicity comparison of a fourth dose of DTaP-IPV//PRP-T (Pentacel) to the Separate Administration of Daptacel and ActHIB [abstract]. In: Abstracts of the 43rd Annual Meeting of the Infectious Diseases Society of America, San Francisco, October 6–9, 2005, Abstract 985.
194. Noriega F, Tsang P, Jemiolo D, et al. And the Pentacel Investigators Immunogenicity Study Group. Immunogenicity of a Four-Dose Series of DTaP-IPV//PRP-T Vaccine (Pentacel) [abstract]. In: Abstracts of the 5th Pediatric Infectious Diseases Conference, Napa Valley, California, October 10–11, 2005.
195. SA Halperin, B Tapiero, B Law, et al. (2006) Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15–20-month-old toddlers. Vaccine 24 4017-4023.
196. MD Decker, KM Edwards, R Bradley, et al. (1992) Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 120 184-189.
197. DP Greenberg, JM Lieberman, SM Marcy, et al. (1995) Enhanced antibody responses in infants given different sequences of heterogeneous Haemophilus influenzae type b conjugate vaccines. J Pediatr 126 206-211.
198. MR Capeding, H Nohynek, LG Pascual, et al. (1996) The immunogenicity of three Haemophilus influenzae type b conjugate vaccines after a primary vaccination series in Philippine infants. Am J Trop Med Hyg 55 516-520.
199. F Mawas, G Newman, S Burns and MJ Corbel (2005) Suppression and modulation of cellular and humoral immune responses to Haemophilus influenzae type B (Hib) conjugate vaccine in hib-diphtheria-tetanus toxoids-acellular pertussis combination vaccines: a study in a rat model. J Infect Dis 191 58-64.
200. F Mawas, R Dickinson, A Douglas-Bardsley, et al. (2006) Immune interaction between components of acellular pertussis-diphtheria-tetanus (DTaP) vaccine and Haemophilus influenzae b (Hib) conjugate vaccine in a rat model. Vaccine 24 3505-3512.
201. DW Scheifele, SA Halperin, B Smith, et al. (2006) Assessment of the compatibility of co-administered 7-valent pneumococcal conjugate, DTaP.IPV/PRP-T Hib and hepatitis B vaccines in infants 2–7 months of age. Vaccine 24 2057-2064.
202. Noriega F, Greenberg DP, Tsang PH, et al, and the Pentacel Vaccine Study Group. Effect of Pneumococcal Conjugate Vaccine (PCV-7) on Antibody Responses to Concomitantly Administered Pentacel (DTaP-IPV//PRP-T) or Licensed-Equivalent Vaccines [abstract]. In: Abstracts of the 43rd Annual Meeting of the Infectious Diseases Society of America, San Francisco, October 6–9, 2005, Abstract 981.
203. Edwards KM, Tsang PH, Lynn Wang L, Noriega F, M5A03 Study Group. Safety and Immunogenicity of DTaP-IPV//PRP-T (Pentacel) Coadministered with Pneumococcal Conjugate Vaccine (Prevnar) at 2, 4, and 6 months of Age [abstract] Abstracts of the 43rd Annual Meeting of the Infectious Diseases Society of America, San Francisco, October 6–9, 2005, Abstract 984
204. SA Halperin, B Tapiero, B Law, et al. (2006) Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15–20 month old toddlers. Vaccine 24 4017-4023.
205. National Advisory Committee on Immunization (2007) Interchangeability of diphtheria, tetanus, acellular pertussis, polio, Haemophilus influenzae type b combination vaccines presently approved for use in Canada for children (7 years of age. Canada Communicable Disease Report 31(ACAS-1), 1-10.
206. MH Slack, D Schapira, RJ Thwaites, et al. (2004) Responses to a fourth dose of Haemophilus influenzae type B conjugate vaccine in early life. Arch Dis Child Fetal Neonatal Ed 89 F269-F271.
207. MH Slack, S Cade, D Schapira, et al. (2005) DT5aP-Hib-IPV and MCC vaccines: preterm infants’ response to accelerated immunisation. Arch Dis Child 90 338-341.
208. F Omeñaca, J Garcia-Sicilia, P Garcia-Corbeira, et al. (2005) Response of preterm newborns to immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B virus-inactivated polio and Haemophilus influenzae type b vaccine: first experiences and solutions to a serious and sensitive issue. Pediatrics 116 1292-1298.
209. H Kayhty, J Eskola, H Peltola, et al. (1991) Antibody response to four Haemophilus influenzae type b conjugate vaccines. Am J Dis Child 145 223-227.
210. G Faldella, S Galletti, L Corvaglia, et al. (2007) Safety of DTaP-IPV-Hib-HBV hexavalent vaccine in very premature infants. Vaccine 22 1036-1042.
211. H Peltola (1998) Haemophilus influenzae type b disease and vaccination in Europe: lessons learned. Pediatr Infect Dis J 17(9 Suppl), S126-S132.
212. Haemophilus influenzae type b disease control using Pentacel, Canada, 1998–1999. Can Commun Dis Rep 26 93-96.
213. Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children-United States, 1998–2000. MMWR 51 234-237.
214. J Fernandez, OS Levine, J Sanchez, et al. (2000) Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration. J Infect Dis 182 1553-1556.
215. M Kauppi, J Eskola and H Kayhty (1995) Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccines. Pediatr Infect Dis J 14 286-294.
216. K Galil, R Singleton, OS Levine, et al. (1999) Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. J Infect Dis 179 101-106.
217. H Kayhty, H Peltola, V Karanko, et al. (1983) The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 147 1100.
218. P Anderson (1984) The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 149 1034.
219. ME Ramsay, J McVernon, NJ Andrews, et al. (2003) Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 188 481-485.
220. JE Berrington, AJ Cant, JN Matthews, et al. (2006) Haemophilus influenzae type b immunization in infants in the United Kingdom: effects of diphtheria/tetanus/acellular pertussis/Hib combination vaccine, significant prematurity, and a fourth dose. Pediatrics 117 e717-e724.
221. J McVernon, N Andrews, MPE Slack and ME Ramsay (2003) Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 361 1521-1523.
222. Health Protection Agency Laboratory reports of Haemophilus influenzae type b infection by age group and quarter: England and Wales: 1990–2004. Online. Available at: http://www.hpa.org.uk/infections/topics_az/Haemophilus_influenzae/data_lab_age_qtr.htm Viewed September 2, 2006
223. Moss SJ, Fenton AC, Toomey J, et al. Decreased immunogenicity of a heptavalent conjugate pneumococcal vaccine (7VCPnc) when administered according to the current UK immunisation schedule [abstract]. In: Abstracts of the 24th Annual Meeting of the European Society for Pediatric Infectious Diseases, Basel, Switzerland, May 2006.
224. H Kalies, T Verstraeten, V Grote, et al. (2004) Erhebungseinheit fur seltene padiatrische Erkrankungen in Deutschland Study Group. Four and one-half-year follow-up of the effectiveness of diphtheria-tetanus toxoids-acellular pertussis/ Haemophilus influenzae type b and diphtheria-tetanus toxoids-acellular pertussis-inactivated poliovirus/ H. influenzae type b combination vaccines in Germany. Pediatr Infect Dis J 23 944-950.
225. Kalies H, Groendahl B, Schmitt H-J, et al. Effectiveness of hexavalent vaccines against invasive Haemophilus influenzae type B disease in Germany [abstract]. In: Abstracts of the 23rd Annual Meeting of the European Society for Pediatric Infectious Diseases, Valencia, Spain, May 2005.
226. Greenberg DP, Doemland ML, Lavigne P, et al, on behalf of the Immunization Monitoring Program, Active (IMPACT). Impact of Pentacel™ (DTaP-IPV//PRP-T) on the Epidemiology of Invasive Hib Disease and Pertussis in Canada. [abstract] Abstracts of the 5th Pediatric Infectious Diseases Conference, Napa Valley, California, October 10–11, 2005.
227. Schmitt HJ, Bock H, Bogaerts H, et al. Single injection of a combined DTPa-Hep B and Hib tetanus conjugate vaccine: a feasibility study [abstract]. In: Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 17–20, 1995, abstract G64.
228. F Zepp, HJ Schmitt, A Kaufhold, et al. (1997) Evidence for induction of polysaccharide specific B-cell-memory in the 1st year of life: plain Haemophilus influenzae type β-PRP (Hib) boosts children primed with a tetanus-conjugate Hib-DTPa-HBV combined vaccine. Eur J Pediatr 156 18-24.
229. J Aristégui, R Dal-Ré, E Garrote, et al. (1998) Assessment of the immunogenicity and reactogenicity of a quadrivalent diphtheria, tetanus, acellular pertussis and hepatitis B (DTPa-HBV) vaccine administered in a single injection with Haemophilus influenzae type b conjugate vaccine, to infants at 2, 4, and 6 months of age. Vaccine 16 1976-1981.
230. F Omeñaca, R Dal-Ré, V D'Apuzzo, et al. (2001) Reactogenicity of DTPa-HBV/Hib vaccine administered as a single injection vs DTPa-HBV and Hib vaccines administered simultaneously at separate sites, to infants at 2, 4, and 6 months of age. Vaccine 19 4260-4266.
231. Heininger U, Schuerman L. Evidence for pre-booster antibody persistence in an open randomised study on infants primed with DTPa-HBV-IPV/Hib or DTPa-IPV/Hib + HBV vaccines at 3, 4, 5 months of age [abstract]. In: Abstracts of the 19th Annual Meeting of the European Society for Paediatric Infectious Diseases, Istanbul, Turkey, March 2001, p 10.
232. Product Information Infanrix® Hexa. Rixensart, Belgium, SmithKline Beecham, 2001.
233. Blatter M, Pichichero M, Harrison C, et al. A combination DTPa-HepB-IPV/Hib vaccine administered to infants at 2,4, and 6 months of age with or without a hepatitis B vaccine birth dose [abstract]. In Abstracts of the 38th Annual Meeting of the Infectious Disease Society of America, New Orleans, September 2000, p 321.
234. ME Pichichero, MM Blatter, KS Reisinger, et al. (2002) Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus- Haemophilus influenzae type b combination vaccination. Pediatr Infect Dis J 21 854-859.
235. Cohen R, Schuerman L. Reactogenicity of a new DTPa-HBV-IPV (+&-Hib) vaccine after the primary and booster doses [abstract]. In: Abstracts of the 18th Annual Meeting of the European Society for Paediatric Infectious Diseases, Noordwijk, the Netherlands, May 3–5, 2000, p 39.
236. Lagos R, Muñoz A, Fabre P, et al. Immunogenicity and safety of a new liquid hexavalent vaccine given at 2, 4, and 6 months of age [abstract]. In: Abstracts of the 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, November 18–21, 1999.
237. JG Liese, S Stojanov, F Berut, et al. (2002) Large scale safety study of a liquid hexavalent vaccine (D-T-acP-IPV-PRPT-HBs) given at 2, 4, 6, and 12 to 14 months of age. Vaccine 20 448-454.
238. Flodmark CE, Schödel L, Hessel L. Immunogenicity and safety of Hexavac administered to healthy Swedish infants at 3, 5, and 12 months of age. Presented at the Pediatric Infectious Diseases Society Conference, Monterey, CA, October 28–30, 2001.
239. Carriere JP, Giard P, Muller JM, et al. Safety and reactogenicity of a liquid hexavalent combined vaccine administered to healthy toddlers aged 16–20 months [abstract]. In: Abstracts of the European Society for Paediatric Infectious Diseases, Noordwijk, the Netherlands, May 3–5, 2000.
240. Stojanov S, Liese JG, Barrand M, et al. Safety profile of a liquid hexavalent vaccine given at 2, 4, and 6 months of age [abstract]. In: Abstracts of the 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, November 18–21, 1999.
241. Crovari P, Zepp F, Dentico P, et al. Immunogenicity and reactogenicity of combined DTPa-HBV-IPV/Hib vaccine compared to concomitant administered DTPa-HBV-IPV and Hib vaccines given at 3, 5, and 11 months of age [abstract]. In: Abstracts of the 19th Annual Meeting of the European Society for Paediatric Infectious Diseases, Istanbul, Turkey, March 2001, p 88.
242. E Mallet, BH Belohradsky, R Lagos, et al. (2004) Hexavalent Vaccine Trial Study Group. A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety. Vaccine 22 1343-1357.
243. F Zepp, M Knuf, U Heininger, et al. (2004) Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants. Vaccine 22 2226-2233.
244. P Reinert, A Fiquet, S Thomas, et al. (2006) Fever as a marker of reactogenicity of an acellular pertussis-containing hexavalent vaccine (HEXAVAC) in a large-scale, open, randomized safety study in healthy French infants. Hum Vaccin 2 215-221.
245. R Lagos, A Hoffenbach, M Scemama, et al. (2005) Lot-to-Lot consistency of a combined hexavalent diptheria-tetanus-acellular-pertussis, hepatitis B, Inactivated polio and haemophilus B conjugate vaccine, administered to healthy, Chilean infants at two, four and six months of age. Hum Vaccin 1 112-117.
246. I Tichmann, H Preidel, D Grunert, et al. (2005) Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine 23 3272-3279.
247. Kilpi T, Silfverdal SA, Nilsson L, et al. Comparison of the immunogenicity and reactogenicity of two hexavalent DTPa-HBV-IPV/ Haemophilus influenzae type b vaccines administered at 3, 5 and 11–12 months of age [abstract]. In: Abstracts of the 24th Annual Meeting of the European Society for Pediatric Infectious Diseases, Basel, Switzerland, May 2006.
248. EMEA European Medicines Agency Press Release: European Medicines Agency recommends suspension of Hexavac. Online. Available at: http://www.emea.eu.int/pdfs/human/press/pr/29736905en.pdf Viewed September 2, 2006
249. EMEA European Medicines Agency Questions and Answers on the suspension of Hexavac. Online. Available at: http://www.emea.eu.int/pdfs/human/press/pr/30488805en.pdf Viewed September 2, 2006
250. Dagan R, Yaich M, Maleckar J, Eskola J. Reduction in antibody responses to an 11-valent pneumococcal vaccine (PncT/D) when coadministered with a vaccine containing acellular pertussis (aP) [abstract]. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 27–30, 2002, abstract G-1069.
251. Schmitt HJ, Petersen G, Corsaro B. Immunogenicity and safety of a 7-valent pneumococcal conjugate vaccine (Prevnar) coadministered with a DTaP-IPV-HBV/Hib vaccine (Infanrix Hexa) [abstract]. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 27–30, 2002, abstract G-835.
252. Olivier C, Liese JG, Stojanov S, et al. Immunogenicity and safety of the 7-valent pneumococcal conjugate vaccine (7VPnC-Prevenar) coadministered with a hexavalent DTaP-IPV-HBV/Hib vaccine (Hexavac) [abstract]. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, September 27–30, 2002, abstract G-836.
253. Saenger R, Dobbelaere K, Schuerman L. Immunogenicity and safety of DTPa-HBV-IPV/Hib coadministered with 7-valent pneumococcal conjugate vaccine. Third World Congress of Pediatric Infectious Diseases (WSPID), Santiago, Chile, November 2002, Abstract 259.
254. Saenger R, Maechler G, Schuerman L. Safety of a booster dose of DTPa-HBV-IPV/HIB compared to concomitant administration of DTPa-IPV/HIB and HBV vaccines. 21st Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), April 2003, Taormina, Sicily, Abstract 257.
255. JC Tejedor, F Omeñaca, F García-Sicilia, et al. (2004) Immunogenicity and reactogenicity of a 3-dose combined primary vaccination course with a combined diphtheria-tetanus-3 component acellular pertussis-hepatitis B-inactivated polio- Haemophilus influenzae type b vaccine co-administered with a meningococcal C conjugate vaccine. Pediatr Infect Dis J 23 1109-1115.
256. JC Tejedor, F Omeñaca, F García-Sicilia, et al. (2006) Antibody persistence after primary vaccination with a hexavalent DTPa-HBV-IPV/Hib vaccine coadministered with a meningococcal C-CRM 197 vaccine and response to a DTPa-IPV/Hib booster at 18 months of age. Pediatr Infect Dis J 25 943-945.
257. Poellabauer EM, Himly C, Loew-Baselli A, et al. Group C meningococcal TT conjugate vaccine (NeisVac-C®)-absence of immunological interference with hepatitis B, IPV, and acellular pertussis (AP). 21st Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), April 2003, Taormina, Sicily, Abstract 207.
258. Vesikari T, Prymula R, Schuster V, et al. Rotarix™ (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with diphtheria-tetanus-pertussis (DTPa)-combined vaccines in healthy infants from Europe. Annual Meeting of the European Society for Pediatric Infectious Diseases, Basle, Switzerland, May 3–5 2006, Poster 383.
259. I Tichmann, H Preidel, D Grunert, et al. (2005) Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine 23 3272-3279.
260. I Tichmann, D Grunert, S Habash, et al. (2006) Persistence of antibodies in children primed with two different hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b vaccines and evaluation of booster vaccination. Human Vaccines 2 249-254.
261. DJ West, TM Hesley, LC Jonas, et al. (1997) Safety and immunogenicity of a bivalent Haemophilus influenzae type b/hepatitis B vaccine in healthy infants. Pediatr Infect Dis J 16 593-599.
262. K Petersen, L Bulkow, B McMahon, et al. (1998) Immunogenicity of a combined hepatitis B and Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. Int J Circumpolar Health 57 285-292.
263. DJ West, GP Rabalais, B Watson, et al. (2001) Antibody responses of healthy infants to concurrent administration of a bivalent Haemophilus influenzae type β-hepatitis B vaccine with diphtheria-tetanus-pertussis, polio and measles-mumps-rubella vaccines. BioDrugs 15 413-418.
264. F Ambrosch, G Wiedermann, FE Andre, et al. (1994) Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine. J Med Virol 44 452-456.
265. RW Joines, M Blatter, B Abraham, et al. (2001) A prospective, randomized, comparative U.S. trial of a combination hepatitis A and B vaccine (Twinrix®) with corresponding monovalent vaccines (Havrix® and Engerix-B®) in adults. Vaccine 19 4710-4719.
266. S Thoelen, P Van Damme, A Leentvaar-Kuypers, et al. (1999) The first combined vaccine against hepatitis A and B: an overview. Vaccine 17 1657-1662.
267. B Abraham, Y Baine, N De Clercq, et al. (2002) Magnitude and quality of antibody response to a combination hepatitis A and hepatitis B vaccine. Antiviral Res 53 63-73.
268. P Van Damme, G Leroux-Roels, B Law, et al. (2001) Long-term persistence (5–6 years) of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J Med Virol 65 6-13.
269. Van Damme P, Leroux-Roels G, Van Herck K, Hoet B. 10 Year Persistence Data for Antibodies Induced by Immunisation with the First Combined Vaccine against hepatitis A and B in Adults [abstract]. In: Abstracts of the 9th Conference of the International Society of Travel Medicine, Lisbon, Portugal, May 1–5, 2005, abstract FC.05.02.
270. HD Nothdurft, M Dietrich, JN Zuckerman, et al. (2002) A new accelerated vaccination schedule for rapid protection against hepatitis A and B. Vaccine 20 1157-1162.
271. M Van der Wielen, D.P. Van Damme P and F Collard (2000) A two-dose schedule for combined hepatitis A and hepatitis B vaccination in children ages one to eleven years. Pediatr Infect Dis J 19 848-853.
272. P Van Damme and M Van der Wielen (2001) Combining hepatitis A and B vaccination in children and adolescents. Vaccine 19 2407-2412.
273. Z Kurugol, F Mutlubas and T Ozacar (2005) A two-dose schedule for combined hepatitis A and B vaccination in children aged 6–15 years. Vaccine 23 2876-2880.
274. D Roberton, H Marshall, TM Nolan, et al. (2005) Reactogenicity and immunogenicity profile of a two-dose combined hepatitis A and B vaccine in 1-11-year-old children. Vaccine 23 5099-5105.
275. B Jarvis and DP Figgitt (2003) Combined Two-Dose Hepatitis A and B Vaccine (AmBirix). Drugs 63 207-213.
276. C Van Hoecke, E Lebaccq, J Beran, et al. (1998) Concomitant vaccination against hepatitis A and typhoid fever. J Travel Med 5 1116-1120.
277. J Beran, M Beutels, K Levie, et al. (2000) A single dose, combined vaccine against typhoid fever and hepatitis A: consistency, immunogenicity and reactogenicity. J Travel Med 7 246-252.
278. D Overbosch, F Peyron, N Picot, et al. (2005) Combined typhoid fever and hepatitis A vaccine: comparison of immunogenicity and safety to concomitant monovalent vaccine over 3 years. J Travel Med 12 319-326.
279. Loebermann M, Kollaritsch H, Chappey O, et al. Immunogenicity and safety of a combined typhoid fever and hepatitis A vaccine in healthy adults [abstract]. In Abstracts of the Seventh Conference of the International Society of Travel Medicine, Innsbruck, Austria, May 27–31, 2001, abstract PO02.16.
280. NJ Beeching, PD Clarke, NR Kitchin, et al. (2004) Comparison of two combined vaccines against typhoid fever and hepatitis A in healthy adults. Vaccine 23 29-35.
281. S Proell, H Maiwald, HD Nothdurft, et al. (2002) Combined vaccination against hepatitis A, hepatitis B, and typhoid fever: safety, reactogenicity, and immunogenicity. J Travel Med 9 122-126.
282. M Just, R Berger and V Just (1986) Evaluation of a combined measles-mumps-rubella-chickenpox vaccine. Dev Biol Stand 65 85-88.
283. Zepp F, Meyer CU, Habermehl P, et al. Cellular immune response to varicella in healthy subjects 12 to 22 months old receiving either a combined measles-mumps-rubella-varicella vaccine or separate measles-mumps-rubella and varicella vaccines [abstract]. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16–19, 2001, abstract G-1560.
284. T Nolan, P McIntyre, D Roberton and D Descamps (2002) Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine 21 281-289.
285. Shinefield H, Black S, Marchant C, et al. A dose selection study in healthy children comparing measles, mumps, rubella, and varicella (ProQuad) vaccine to M-M-R II given concomitantly with process upgrade varicella vaccine (PUVV) in separate injections [abstract]. In: Abstracts of the 20th Annual Meeting of the European Society for Paediatric Infectious Diseases, Vilnius, Lithuania, May 2002.
286. HH Bernstein, K Eves, K Campbell, et al. (2007) Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (Measles, Mumps, Rubbela, and Varicella Virus Vaccine Live). Pediatr 119 e1299-e1305.
287. Carmona A, Miranda M, Fuente F, et al. Immunogenicity, safety and reactogenicity of a booster dose of a Haemophilus influenzae Type b and Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate (Hib-MenC-TT) vaccine co-administered with MMR (measles-mumps-rubella) vaccine [abstract]. In: Abstracts of the 24th Annual Meeting of the European Society for Pediatric Infectious Diseases, Basel, Switzerland, May 2006.
288. Habermehl P, Leroux-Roels G, Sänger R, et al. Immunogenicity and reactogenicity of a combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C-tetanus toxoid conjugate (Hib-MenC-TT) vaccine administered as a primary at 2, 3 and 4 months and as a booster at second year of life [abstract]. In: Abstracts of the 24th Annual Meeting of the European Society for Pediatric Infectious Diseases, Basel, Switzerland, May 2006.
289. Pace D, Snape MD, Westcar S, et al. Immunogenicity, safety and reactogenicity of a combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine in infants [abstract]. In: Abstracts of the 24th Annual Meeting of the European Society for Pediatric Infectious Diseases, Basel, Switzerland, May 2006.
290. Tejedor JC, Moro M, Gómez-Campderá JA, et al. A novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C-tetanus toxoid conjugate (Hib-MenC-TT) vaccine at 2, 4 and 6 months induces persistent immune response and a Hib-MenC-TT booster dose is highly immunogenic and well-tolerated [abstract]. In: Abstracts of the 24 th Annual Meeting of the European Society for Pediatric Infectious Diseases, Basel, Switzerland, May 2006.
291. Tejedor JC, Moro M, Ruiz-Contreras J, et al. Immunogenicity and reactogenicity of a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C-tetanus toxoid conjugate (Hib-MenC-TT) vaccine coadministered with a pentavalent DTPa-HBV-IPV vaccine at 2, 4 and 6 months [abstract]. In: Abstracts of the 24th Annual Meeting of the European Society for Pediatric Infectious Diseases, Basel, Switzerland, May 2006.
292. HJ Schmitt, G Maechler, P Habermehl, et al. (2007) Immunogenicity, reactogenicity, and immune memory after primary vaccination with a novel Haemophilus influenzae-Neisseria meningitidis serogroup C conjugate vaccine. Clin Vaccine Immunol 14 426-434.
293. JC Tejedor, M Moro, J Ruiz-Contreras, et al. (2007) Immunogenicity and reactogenicity of primary immunization with a novel combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine coadministered with a diphtheria-tetanus-acellular pertussis-hepatitis β-inactivated poliovirus vaccine at 2, 4 and 6 Months. Pediatr Infcect Dis J 26 1-7.
294. Miller J, Friedland LR, de La Bourdonnaye G, et al. Immunogenicity and safety of an investigational combined Haemophilus influenzae type B and Neisseria meningitidis serogroups C and Y conjugate vaccine in healthy infants compared to licensed controls. Postr P178, Pediatric Academic Societies annual meeting, Toronto, Canada, May 5–8 2007.
295. Schmitt HJ, Leroux-Roels G, Lebacq E, et al. Combination diphtheria-tetanus-acellular pertussis-hepatitis β-inactivated polio and Haemophilus influenzae type b-meningococcal C conjugate vaccine. 21st Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), April 2003, Taormina, Sicily, Abstract 293.
296. S Choo, L Seymour, R Morris, et al. (2000) Immunogenicity and reactogenicity of a pneumococcal conjugate vaccine administered combined with a Haemophilus influenzae type b conjugate vaccine in United Kingdom infants. Pediatr Infect Dis J 19 854-862.
297. Rennels M, Reisinger K, Rathore M, et al. Safety and immunogenicity of combined conjugate 9-valent S. pneumoniae-meningococcal group C (9vPnC-MnCC) and H. influenzae β-9vPnC-MnCC (HbOC-9vPnC-MnCC) vaccine [abstract]. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December 16–19, 2001, abstract G-2039.
298. JP Buttery, A Riddell, J McVernon, et al. (2005) Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial. JAMA 293 1751-1758.
299. A Riddell, JP Buttery, J McVernon, et al. (2007) A randomized study comparing the safety and immunogenicity of a conjugate vaccine combination containing meningococcal group C and pneumococcal capsular polysaccharide-CRM(197) with a meningococcal group C conjugate vaccine in healthy infants: Challenge phase. Vaccine 25 3906-3912.
300. Sanofi Pasteur reforzó su presencia en Argentina Esencia, January-February 2006. Online. Available at: http://www.farmaciaesencia.com/Revista_esencia/mes/Enero_2006/Inauguracion.asp Viewed September 2, 2006
301. SA Halperin, JM Langley, TM Hesley, et al. (2005) Safety and immunogenicity of two formulations of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae conjugate-hepatitis B vaccine in 15 to 18-month-old children. Hum Vaccin 6 245-250.
302. Centers for Disease Control and Prevention (1999) Combination vaccines for childhood immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP), and the American Academy of Family Physicians (AAFP). MMWR 48(RR-5),
303. American Academy of Pediatrics (2000) Scheduling immunizations. LK Pickering (Ed.) 2000 Red Book: Report of the Committee on Infectious Diseases, 25th ed Elk Grove Village, IL: American Academy of Pediatrics 20-26.
304. AS Meyerhoff and RJ Jacobs (2005) Do too many shots due lead to missed vaccination opportunities. Does it matter? [abstract] Prev Med 41 540-544.
305. Koslap-Petraco M, Iftikhar O. Combination vaccines—how they helped improve immunization rates in health centers in Suffolk County, NY [abstract]. In: Abstracts of the 40th National Immunization Conference, Atlanta, Georgia, March 6–9, 2006, abstract 225.
306. Marshall GS, Happe LE, Russell A. Timeliness of Childhood Immunizations in a State Medicaid Population [abstract]. In: Abstracts of the 40th National Immunization Conference, Atlanta, Georgia, March 6–9, 2006, abstract 264.
307. Marshall GS, Happe L, Russell A. Coverage rates among children receiving combination versus component vaccines in a state Medicaid population [abstract]. In: Abstracts of the 40th National Immunization Conference, Atlanta, Georgia, March 6–9, 2006, abstract 267.
308. Happe L, Larsen D, Lunacsek O, Chiao E. Timeliness of childhood immunizations among children exposed to combination vaccines and single-agent vaccines in a managed care health plan [abstract]. In: Abstracts of the Academy of Managed Care Pharmacy 18th Annual Meeting & Showcase, Seattle, WA, April 5–8, 2006.
309. H Kalies, V Grote, HJ Schmitt and R von Kries (2006) Immunisation status of children in Germany: temporal trends and regional differences. Eur J Pediatr 165 30-36.
310. H Kalies, V Grote, T Verstraeten, et al. (2006) The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis J 25 507-512.
311. EL Anderson, MD Decker, JA Englund, et al. (1995) Interchangeability of conjugated Haemophilus influenzae type b vaccines in infants. JAMA 273 849-853.
312. Centers for Disease Control and Prevention (1997) Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 46 19.
313. Pertussis. In Atkinson W, Wolfe C, (eds). Epidemiology and Prevention of Vaccine-Preventable Diseases, 7th ed. Atlanta, Centers for Disease Control and Prevention, 2002.
314. Centers for Disease Control and Prevention (2005) Immunization information system progress—United States, 2004. MMWR 54 1156-1157.